We are live on ! Find out more
VKTX icon

Viking Therapeutics

422 hedge funds and large institutions have $5.25B invested in Viking Therapeutics in 2024 Q3 according to their latest regulatory filings, with 94 funds opening new positions, 179 increasing their positions, 101 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $464M | Put options by funds: $242M

77% more repeat investments, than reductions

Existing positions increased: 179 | Existing positions reduced: 101

65% more first-time investments, than exits

New positions opened: 94 | Existing positions closed: 57

33% more funds holding in top 10

Funds holding in top 10: 68 (+2)

23% more capital invested

Capital invested by funds: $4.26B → $5.25B (+$987M)

9% more funds holding

Funds holding: 387422 (+35)

2.82% more ownership

Funds ownership: 72.94%75.76% (+2.8%)

Holders
422
Holders Change
+35
Holders Change %
+9.04%
% of All Funds
6.06%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
94
Increased
179
Reduced
101
Closed
57
Calls
$464M
Puts
$242M
Net Calls
+$222M
Net Calls Change
-$14.8M
Name Holding Trade Value Shares
Change
Change in
Stake
IFWM
151
Institute for Wealth Management
Colorado
$2.29M +$253K +4,317 +14%
Osaic Holdings
152
Osaic Holdings
Arizona
$2.29M +$469K +8,002 +28%
WA
153
Waverly Advisors
Alabama
$2.28M -$681K -11,613 -24%
Amundi
154
Amundi
France
$2.24M +$1.97M +33,554 New
CM
155
Castleark Management
Illinois
$2.22M +$9.97K +170 +0.5%
SC
156
Shay Capital
New York
$2.18M -$747K -12,734 -27%
Bank of Montreal
157
Bank of Montreal
Ontario, Canada
$2.17M +$1.75M +29,819 +549%
Squarepoint
158
Squarepoint
New York
$2.17M -$6.31M -107,566 -76%
MASUI
159
MIRAE ASSET SECURITIES (USA) INC.
New York
$2.15M +$2M +34,036 New
Rockefeller Capital Management
160
Rockefeller Capital Management
New York
$2.15M +$1.04M +17,754 +109%
FAM
161
Formidable Asset Management
Ohio
$2.11M +$448K +7,639 +30%
BPA
162
Beacon Pointe Advisors
California
$2.08M +$1.93M +32,864 New
AG
163
Algert Global
California
$1.98M -$134K -2,280 -7%
EAM
164
EFG Asset Management
Oregon
$1.97M +$715K +12,192 +64%
LAM
165
Lewis Asset Management
California
$1.92M +$232K +3,950 +15%
CC
166
Cornerstone Capital
California
$1.88M -$245K -4,180 -12%
ASRS
167
Arizona State Retirement System
Arizona
$1.81M +$60K +1,023 +4%
Skandinaviska Enskilda Banken (SEB)
168
Skandinaviska Enskilda Banken (SEB)
Sweden
$1.8M
Thrivent Financial for Lutherans
169
Thrivent Financial for Lutherans
Minnesota
$1.79M +$43.9K +748 +3%
EGM
170
Engineers Gate Manager
New York
$1.74M +$1.04M +17,675 +182%
CAM
171
ClariVest Asset Management
California
$1.7M
Wealth Enhancement Advisory Services
172
Wealth Enhancement Advisory Services
Minnesota
$1.63M +$585K +9,965 +63%
Calamos Advisors
173
Calamos Advisors
Illinois
$1.61M +$807K +13,760 +118%
GC
174
Guggenheim Capital
Illinois
$1.6M -$153K -2,613 -9%
Teacher Retirement System of Texas
175
Teacher Retirement System of Texas
Texas
$1.58M +$192K +3,276 +15%

VKTX Hedge Fund Activity: Q3 2024 in Review

422 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2024, worth a combined $5.25B — up 23% from $4.26B a quarter earlier.

Buyers outnumbered sellers: 94 funds opened new VKTX positions and 57 closed out — a net gain of 37 holders — while 179 added to existing stakes and 101 trimmed.

The largest buyer was Norges Bank, adding an estimated $63.8M. The largest seller was Goldman Sachs, cutting an estimated $53.8M.

  • 422 institutional investors held Viking Therapeutics (VKTX) as of Q3 2024, up from 387 in Q2 2024.
  • Funds reported $5.25B of Viking Therapeutics stock for Q3 2024, up 23% quarter-over-quarter.
  • 94 funds opened new Viking Therapeutics positions in Q3 2024 and 57 closed out, a net change of +37 holders.
  • The largest Viking Therapeutics buyer in Q3 2024 was Norges Bank, an estimated $63.8M added.
  • The largest Viking Therapeutics seller in Q3 2024 was Goldman Sachs, an estimated $53.8M sold.

Based on aggregated 13F filings for Q3 2024.